<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4895">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948102</url>
  </required_header>
  <id_info>
    <org_study_id>CHS-Neurology_ALS_TDI_PEG</org_study_id>
    <nct_id>NCT01948102</nct_id>
  </id_info>
  <brief_title>Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples</brief_title>
  <official_title>Identification of Diagnostic and Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benjamin Brooks</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALSTDI (ALS Therapy Development Institute)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Carolinas Healthcare System</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the project is to obtain skin and adipose tissue samples from patients with
      ALS to develop new diagnostic and prognostic markers of the disease.  These samples will be
      obtained when percutaneous endoscopic gastrostomy (PEG) is performed as part of their
      standard of care.  Skin and adipose tissue samples will also be obtained from disease
      control subjects who require a PEG as part of their standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Abundance levels of the known messenger RNA transcriptome  of skin  and adipose tissue samples (measured by gene expression profiling)</measure>
    <time_frame>After tissue has been collected from study subjects.  Data will be analyzed at 1 year.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in abundance of or post-translational modification of proteins (measured by proteomics)</measure>
    <time_frame>After tissue has been collected from study subjects.  Data will be analzyed at year 1 after primary outcome data has been reviewed and analyzed</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>subjects with ALS</arm_group_label>
    <description>subjects with ALS who are undergoing a percutaneous endoscopic gastrostomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subjects without ALS</arm_group_label>
    <description>subjects without ALS who are undergoing a percutaneous endoscopic gastrostomy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      skin and adipose tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at the Carolinas Neuromuscular/ALS-MDA Center and patients at Carolinas Medical
        Center.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  for ALS patients, subjects must be diagnosed with definite ALS according to the El
             Escorial Critera (EEC)

          -  all subjects must be diagnosed with a condition requiring PEG (percutaneous
             endoscopic gastrostomy) tube insertion

          -  subjects must be older than 18 years of age

        Exclusion Criteria:

          -  children 18 years old and younger
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Pacicco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolinas Medical Center - Dept of Gastroenterology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia Lary</last_name>
    <phone>704-446-6063</phone>
    <email>cynthia.lary@carolinashealthcare.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carissa Tonkins</last_name>
    <phone>704-446-0836</phone>
    <email>carissa.tonkins@carolinashealthcare.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Carolinas Medical Center - Dept of Neurology</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Lary</last_name>
      <phone>704-446-6063</phone>
      <email>cynthia.lary@carolinashealthcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Carissa Tonkins</last_name>
      <phone>704-446-0836</phone>
      <email>carissa.tonkins@carolinashealthcare.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 18, 2013</lastchanged_date>
  <firstreceived_date>March 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Carolinas Healthcare System</investigator_affiliation>
    <investigator_full_name>Benjamin Brooks</investigator_full_name>
    <investigator_title>Director, Neuromuscular/ ALS-MDA Center and Neuromuscular/ ALS Research Laboratory</investigator_title>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>motor neuron disease</keyword>
  <keyword>biological markers</keyword>
  <keyword>biomarkers</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
